{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:52:56Z","timestamp":1781635976967,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFC2706405 and 2022YFC2705300"],"award-info":[{"award-number":["2023YFC2706405 and 2022YFC2705300"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-5082"],"award-info":[{"award-number":["2024-2-5082"]}]},{"name":"key project of innovation cultivation fund of the Seventh Medical Center of Chinese PLA General Hospital","award":["QZX-2023-1"],"award-info":[{"award-number":["QZX-2023-1"]}]},{"name":"Innovation Talent Fund of Senior Department of Pediatrics, The Seventh Medical Center of PLA General Hospital","award":["QZX-04-EKLHJH-3"],"award-info":[{"award-number":["QZX-04-EKLHJH-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Late-onset Pompe disease (LOPD) is an autosomal-recessive disorder caused by acid \u03b1-glucosidase (GAA) deficiency, typically presenting after the first year of life and resulting in systemic glycogen accumulation. Beyond motor and respiratory manifestations, gastrointestinal (GI) symptoms have been increasingly reported. Although enzyme replacement therapy (ERT) improves skeletal and respiratory function, its impact on GI symptoms remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>There were 124 LOPD patients recruited to complete the Gastrointestinal Symptom Rating Scale (GSRS), together with questionnaires on clinical manifestations and demographic data. Spearman\u2019s correlation and multiple linear regression were used to analyze the factors associated with GI symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cross-sectional study, patients receiving standard-dose ERT (20 mg\/kg, biweekly) exhibited the mildest GI symptoms compared with untreated patients and those on reduced-dose ERT (&lt;\u200920 mg\/kg or &lt;\u2009biweekly). Lower family income, reduced ERT dosage, requirement for respiratory support, and tongue hypertrophy or atrophy were associated with more severe GI symptoms. With increasing ERT dose, improvements in scores of halitosis, loose stools, and the dyspepsia domain were most pronounced, and the time to onset of obvious GI symptoms was correspondingly delayed. However, longer ERT duration correlated positively with constipation severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GI symptoms in LOPD are influenced by income, involvement of other organs or systems, and treatment-related factors. Standard-dose ERT significantly alleviates abdominal pain, diarrhea, and dyspepsia, but may exacerbate constipation over time. Future studies should explore novel therapeutic strategies to improve GI symptoms and nutritional status in patients with LOPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04171-8","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:53:37Z","timestamp":1770728017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal manifestations and enzyme replacement therapy in late-onset Pompe disease: insights from a cross-sectional analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Xinting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-2146","authenticated-orcid":false,"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"4171_CR1","doi-asserted-by":"publisher","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342-53. https:\/\/doi.org\/10.1016\/s0140-6736(08)61555-x.","DOI":"10.1016\/s0140-6736(08)61555-x"},{"key":"4171_CR2","doi-asserted-by":"publisher","unstructured":"Hers HG. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease). Biochem J. 1963;86:11\u2009\u2013\u20096. https:\/\/doi.org\/10.1042\/bj0860011.","DOI":"10.1042\/bj0860011"},{"key":"4171_CR3","doi-asserted-by":"publisher","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267\u2009\u2013\u200988. https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3.","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"4171_CR4","doi-asserted-by":"publisher","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671-6. https:\/\/doi.org\/10.1016\/j.jpeds.2005.11.033.","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"4171_CR5","doi-asserted-by":"publisher","unstructured":"Bay LB, Denzler I, Durand C, Eiroa H, Frabasil J, Fainboim A et al. Infantile-onset Pompe disease: diagnosis and management. Arch Argent Pediatr. 2019;117(4):271-8. https:\/\/doi.org\/10.5546\/aap.2019.eng.271.","DOI":"10.5546\/aap.2019.eng.271"},{"key":"4171_CR6","doi-asserted-by":"publisher","unstructured":"Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3):163\u2009\u2013\u200972. https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.004.","DOI":"10.1016\/j.ymgme.2016.12.004"},{"key":"4171_CR7","doi-asserted-by":"publisher","unstructured":"Labella B, Cotti Piccinelli S, Risi B, Caria F, Damioli S, Bertella E et al. A comprehensive update on late-onset Pompe disease. Biomolecules. 2023;13(9). https:\/\/doi.org\/10.3390\/biom13091279.","DOI":"10.3390\/biom13091279"},{"key":"4171_CR8","doi-asserted-by":"publisher","unstructured":"McCall AL, Salemi J, Bhanap P, Strickland LM, Elmallah MK. The impact of Pompe disease on smooth muscle: a review. J Smooth Muscle Res. 2018;54(0):100\u2009\u2013\u200918. https:\/\/doi.org\/10.1540\/jsmr.54.100.","DOI":"10.1540\/jsmr.54.100"},{"key":"4171_CR9","doi-asserted-by":"publisher","unstructured":"Korlimarla A, Lim JA, McIntosh P, Zimmerman K, Sun BD, Kishnani PS. New insights into gastrointestinal involvement in late-onset Pompe disease: Lessons Learned from Bench and Bedside. J Clin Med. 2021;10(15). https:\/\/doi.org\/10.3390\/jcm10153395.","DOI":"10.3390\/jcm10153395"},{"key":"4171_CR10","doi-asserted-by":"publisher","unstructured":"Karabul N, Skudlarek A, Berndt J, Kornblum C, Kley RA, Wenninger S et al. Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey. JIMD Rep. 2014;17:53\u201361. https:\/\/doi.org\/10.1007\/8904_2014_334.","DOI":"10.1007\/8904_2014_334"},{"key":"4171_CR11","doi-asserted-by":"publisher","unstructured":"Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab. 2010;101(2\u20133):130-3. https:\/\/doi.org\/10.1016\/j.ymgme.2010.06.003.","DOI":"10.1016\/j.ymgme.2010.06.003"},{"key":"4171_CR12","doi-asserted-by":"publisher","unstructured":"Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800\u2009\u2013\u200910. https:\/\/doi.org\/10.1038\/gim.2012.44.","DOI":"10.1038\/gim.2012.44"},{"key":"4171_CR13","doi-asserted-by":"publisher","unstructured":"Pardo J, Garc\u00eda-Sobrino T, L\u00f3pez-Ferreiro A. Gastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapy. J Neurol Sci. 2015;353(1\u20132):181-2. https:\/\/doi.org\/10.1016\/j.jns.2015.04.012.","DOI":"10.1016\/j.jns.2015.04.012"},{"issue":"Suppl 1","key":"4171_CR14","first-page":"114","volume":"12","author":"PS Kishnani","year":"2014","unstructured":"Kishnani PS, Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev. 2014;12(Suppl 1):114\u201324.","journal-title":"Pediatr Endocrinol Rev"},{"key":"4171_CR15","doi-asserted-by":"publisher","unstructured":"Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319\u2009\u2013\u200933. https:\/\/doi.org\/10.1002\/mus.22329.","DOI":"10.1002\/mus.22329"},{"key":"4171_CR16","doi-asserted-by":"publisher","unstructured":"Gesqui\u00e8re-Dando A, Attarian S, Maues De Paula A, Pouget J, Salort-Campana E. Fibromyalgia-like symptoms associated with irritable bowel syndrome: a challenging diagnosis of late-onset Pompe disease. Muscle Nerve. 2015;52(2):300-4. https:\/\/doi.org\/10.1002\/mus.24618.","DOI":"10.1002\/mus.24618"},{"key":"4171_CR17","doi-asserted-by":"publisher","unstructured":"van der Walt JD, Swash M, Leake J, Cox EL. The pattern of involvement of adult-onset acid maltase deficiency at autopsy. Muscle Nerve. 1987;10(3):272\u2009\u2013\u200981. https:\/\/doi.org\/10.1002\/mus.880100311.","DOI":"10.1002\/mus.880100311"},{"key":"4171_CR18","doi-asserted-by":"publisher","unstructured":"Hobson-Webb LD, Proia AD, Thurberg BL, Banugaria S, Prater SN, Kishnani PS. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab. 2012;106(4):462-9. https:\/\/doi.org\/10.1016\/j.ymgme.2012.05.007.","DOI":"10.1016\/j.ymgme.2012.05.007"},{"key":"4171_CR19","doi-asserted-by":"publisher","unstructured":"Roberts M, Kishnani PS, van der Ploeg AT, M\u00fcller-Felber W, Merlini L, Prasad S et al. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe registry. Mol Genet Metab. 2011;104(4):574\u2009\u2013\u200982. https:\/\/doi.org\/10.1016\/j.ymgme.2011.08.011.","DOI":"10.1016\/j.ymgme.2011.08.011"},{"key":"4171_CR20","doi-asserted-by":"publisher","unstructured":"WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86\u201395. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.tb02379.x.","DOI":"10.1111\/j.1651-2227.2006.tb02379.x"},{"key":"4171_CR21","doi-asserted-by":"publisher","unstructured":"Dup\u00e9 C, Lefeuvre C, Sol\u00e9 G, Behin A, Pottier C, Duval F et al. Macroglossia: a potentially severe complication of late-onset Pompe disease. Eur J Neurol. 2022;29(7):2121-8. https:\/\/doi.org\/10.1111\/ene.15330.","DOI":"10.1111\/ene.15330"},{"key":"4171_CR22","doi-asserted-by":"publisher","unstructured":"Al-Hashel J, Ismail I. Late-onset Pompe disease presenting with isolated tongue involvement. Case Rep Neurol. 2022;14(1):98\u2013103. https:\/\/doi.org\/10.1159\/000521524.","DOI":"10.1159\/000521524"},{"key":"4171_CR23","doi-asserted-by":"publisher","unstructured":"Svedlund J, Sj\u00f6din I, Dotevall G. GSRS\u2013a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129\u2009\u2013\u200934. https:\/\/doi.org\/10.1007\/bf01535722.","DOI":"10.1007\/bf01535722"},{"key":"4171_CR24","doi-asserted-by":"publisher","unstructured":"Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7(1):75\u201383. https:\/\/doi.org\/10.1023\/a:1008841022998.","DOI":"10.1023\/a:1008841022998"},{"key":"4171_CR25","doi-asserted-by":"publisher","unstructured":"Kulich KR, Madisch A, Pacini F, Piqu\u00e9 JM, Regula J, Van Rensburg CJ et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008;6:12. https:\/\/doi.org\/10.1186\/1477-7525-6-12.","DOI":"10.1186\/1477-7525-6-12"},{"key":"4171_CR26","doi-asserted-by":"publisher","unstructured":"Witkowski G, Konopko M, Rola R, \u0141ugowska A, Ryglewicz D, Sienkiewicz-Jarosz H. Enzymatic replacement therapy in patients with late-onset Pompe disease \u2013\u20096-Year follow up. Neurol Neurochir Pol. 2018;52(4):465-9. https:\/\/doi.org\/10.1016\/j.pjnns.2018.05.002.","DOI":"10.1016\/j.pjnns.2018.05.002"},{"key":"4171_CR27","doi-asserted-by":"publisher","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91\u2009\u2013\u20097. https:\/\/doi.org\/10.1007\/s00415-009-5275-3.","DOI":"10.1007\/s00415-009-5275-3"},{"key":"4171_CR28","doi-asserted-by":"publisher","unstructured":"Koloski N, Holtmann G, Talley NJ. Is there a causal link between psychological disorders and functional gastrointestinal disorders? Expert Rev Gastroenterol Hepatol. 2020;14(11):1047-59. https:\/\/doi.org\/10.1080\/17474124.2020.1801414.","DOI":"10.1080\/17474124.2020.1801414"},{"key":"4171_CR29","doi-asserted-by":"publisher","unstructured":"Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II\/Pompe Disease. Neurotherapeutics. 2008;5(4):569\u2009\u2013\u200978. https:\/\/doi.org\/10.1016\/j.nurt.2008.08.009.","DOI":"10.1016\/j.nurt.2008.08.009"},{"key":"4171_CR30","doi-asserted-by":"publisher","unstructured":"Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L et al. Management and treatment of glycogenosis type II. Neurology. 2008;71(23 Suppl 2):S12-36. https:\/\/doi.org\/10.1212\/WNL.0b013e31818da93f.","DOI":"10.1212\/WNL.0b013e31818da93f"},{"key":"4171_CR31","doi-asserted-by":"publisher","unstructured":"Bar-On E, Harari M, Floman Y, Bar-Ziv J, Maayan C. Compression of the esophagus by the spine and the aorta in untreated scoliosis. Arch Orthop Trauma Surg. 1998;117(6\u20137):405-7. https:\/\/doi.org\/10.1007\/s004020050280.","DOI":"10.1007\/s004020050280"},{"key":"4171_CR32","doi-asserted-by":"publisher","unstructured":"Lee SB, Chae HW, Kwon JW, Sung S, Moon SH, Suk KS et al. Association of functional gastrointestinal disorders with adolescent idiopathic scoliosis. Children (Basel). 2024;11(1). https:\/\/doi.org\/10.3390\/children11010118.","DOI":"10.3390\/children11010118"},{"key":"4171_CR33","doi-asserted-by":"publisher","unstructured":"Jones HN, Hobson-Webb LD, Kuchibhatla M, Crisp KD, Whyte-Rayson A, Batten MT et al. Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired\/hereditary myopathy. Mol Genet Metab. 2021;133(3):261-8. https:\/\/doi.org\/10.1016\/j.ymgme.2021.05.005.","DOI":"10.1016\/j.ymgme.2021.05.005"},{"key":"4171_CR34","doi-asserted-by":"publisher","unstructured":"Su HT, Wang LM, Yang CF, Lee LH, Brajot FX. Language, speech, and oromotor function in children with Pompe disease. Neuromuscul Disord. 2020;30(5):400\u2009\u2013\u200912. https:\/\/doi.org\/10.1016\/j.nmd.2020.03.003.","DOI":"10.1016\/j.nmd.2020.03.003"},{"key":"4171_CR35","doi-asserted-by":"publisher","unstructured":"Putensen C, Wrigge H, Fau - Hering R, Hering R. The effects of mechanical ventilation on the gut and abdomen. Curr Opin Crit Care. 2006;12(1070\u20135295 (Print)):160-5. https:\/\/doi.org\/10.1097\/01.ccx.0000216585.54502.eb.","DOI":"10.1097\/01.ccx.0000216585.54502.eb"},{"issue":"2","key":"4171_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mdc3.13134","volume":"8","author":"JE Kenna","year":"2021","unstructured":"Kenna JE, Bakeberg MC, Gorecki AM, Chin Yen Tay A, Winter S, Mastaglia FL, et al. Characterization of gastrointestinal symptom type and severity in parkinson\u2019s disease: a case-control study in an Australian cohort. Mov Disord Clin Pract. 2021;8(2):245\u201353.","journal-title":"Mov Disord Clin Pract"},{"key":"4171_CR37","doi-asserted-by":"publisher","unstructured":"Ajay D, McNamara ER, Austin S, Wiener JS, Kishnani P. Lower urinary tract symptoms and incontinence in children with Pompe disease. JIMD Rep. 2016;28:59\u201367. https:\/\/doi.org\/10.1007\/8904_2015_492.","DOI":"10.1007\/8904_2015_492"},{"key":"4171_CR38","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17(9\u201310):698\u2013706. https:\/\/doi.org\/10.1016\/j.nmd.2007.06.002.","DOI":"10.1016\/j.nmd.2007.06.002"},{"key":"4171_CR39","doi-asserted-by":"publisher","unstructured":"Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab. 2005;85(4):255-9. https:\/\/doi.org\/10.1016\/j.ymgme.2005.04.009.","DOI":"10.1016\/j.ymgme.2005.04.009"},{"issue":"6","key":"4171_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","volume":"71","author":"A Zimran","year":"1992","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Med (Baltim). 1992;71(6):337\u201353.","journal-title":"Med (Baltim)"},{"key":"4171_CR41","doi-asserted-by":"publisher","unstructured":"Verderese CL, Graham OC, Holder-McShane CA, Harnett NE, Barton NW. Gaucher\u2019s disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs. 1993;25(5):296\u2013301. https:\/\/doi.org\/10.1097\/01376517-199310000-00005.","DOI":"10.1097\/01376517-199310000-00005"},{"key":"4171_CR42","doi-asserted-by":"publisher","unstructured":"McCall AL, Dhindsa JS, Bailey AM, Pucci LA, Strickland LM, ElMallah MK. Glycogen accumulation in smooth muscle of a Pompe disease mouse model. J Smooth Muscle Res. 2021;8\u201318(1884\u20138796 (Electronic)):8\u201318. https:\/\/doi.org\/10.1540\/jsmr.57.8.","DOI":"10.1540\/jsmr.57.8"},{"key":"4171_CR43","doi-asserted-by":"publisher","unstructured":"Bijvoet AG, van de Kamp EH, Kroos MA, Ding JH, Yang BZ, Visser P et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet. 1998;7(1):53\u201362. https:\/\/doi.org\/10.1093\/hmg\/7.1.53.","DOI":"10.1093\/hmg\/7.1.53"},{"key":"4171_CR44","doi-asserted-by":"publisher","unstructured":"Pena LD, Proia AD, Kishnani PS. Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease. JIMD Rep. 2015;23:45\u201354. https:\/\/doi.org\/10.1007\/8904_2015_426.","DOI":"10.1007\/8904_2015_426"},{"key":"4171_CR45","doi-asserted-by":"publisher","unstructured":"Fuller DD, ElMallah M, Fau - Smith BK, Smith Bk Fau - Corti M, Corti M, Fau - Lawson LA et al. Lawson La Fau - Falk DJ, Falk Dj Fau - Byrne BJ,. The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol. 2013;189(1878\u2009\u2013\u20091519 (Electronic)):241-9. https:\/\/doi.org\/10.1016\/j.resp.2013.06.007.","DOI":"10.1016\/j.resp.2013.06.007"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04171-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:01:15Z","timestamp":1781632875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04171-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04171-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was granted by the Ethics Committee of the First Medical Center of the PLA General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patients have been given their informed consent for us to publish the findings from our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"50"}}